[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"treatment-resistant-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:treatment-resistant-hypertension":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100558844","effect-of-renal-denervation-on-bood-pressure-in-patients-on-hemodialysis-100558844",false,"NCT06556407","Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis","Effect of Renal Denervation on Blood Pressure in Patients With Treatment Resistant Hypertension, End-stage Chronic Kidney Disease and Hemodialysis","RDN-HD","Inclusion Criteria:\n\n* Uncontrolled treatment resistant hypertension (despite intake of 3 different classes of antihypertensive medications) confirmed by 24-h ambulatory blood pressure according to current guidelines (ESH 2023) (office blood pressure ≥ 140\u002F and\u002F or ≥ 90 mmHg and ambulatory blood pressure ≥ 130\u002F and\u002For ≥ 80 mmHg\n* end-stage renal disease on chronic hemodialysis\n* Stable hemodialysis regime for at least 3 months based on the decision of the treating physician\n* Patient is adhering to a stable drug regimen without changes for a minimum of 4 weeks.\n* Individual is ≥ 18 years of age, male and female patients are included.\n\nExclusion Criteria:\n\n* Episodes of sustained systolic and\u002For diastolic hypotension according to 24-h ambulatory blood pressure or dialysis protocols which in the eyes of the treating physician would interfere with a safe renal denervation treatment of the patient\n* Known hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which in the eyes of the interventionalist would interfere with safe catheter placement\n* Prior renal denervation procedure\n* Anatomic or functional solitary kidney, kidney transplantation\n* Severe atherosclerotic disease or artery calcification preventing the assessment of reliable BP measurements\n* Endocrine hypertension other than obstructive sleep apnea\n* Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit\n* Acute episode of systemic and renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months\n* Subject is pregnant, nursing, or intends to become pregnant\n* Enrollment in another interventional research protocol.\n* Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)","ALL","18 Years","99 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"NA","The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.",[28,29],"Treatment Resistant Hypertension","Chronic Hemodialysis","RECRUITING","2025-09-22",{"date":33,"type":34},"2025-09-26","ACTUAL",{"date":36,"type":34},"2024-03-04",{"date":38,"type":22},"2026-12-01",{"name":40,"class":41},"University of Erlangen-Nürnberg Medical School","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100588331","phase-2-endocalyx-in-treatment-resistent-hypertension-100588331","NCT06940011","Endocalyx in Treatment Resistent Hypertension","Glycocalyx Restoration in Treatment Resistant Hypertension: a Proof of Concept, Randomized, Double-blind, Placebo-controlled Study","GLYCO-TRH","Inclusion Criteria:\n\n1. Treatment resistant hypertension defined as\n\n   1. an uncontrolled office BP (≥140\u002F90 mmHg).\n   2. is on a regimen of ≥3 adequately dosed antihypertensive agents of different classes, including a diuretic, at maximum tolerated dose based on investigator judgment.\n2. Stable diuretic and antihypertensive treatment for the previous 3 weeks.\n3. Subject, or legal representative, has voluntarily signed and dated an Informed Consent Form, approved by the Independent Ethics Committee (IEC).\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years.\n2. Estimated glomerular filtration rate (eGFR) \\\u003C20 ml\u002Fmin\u002F1.73m2 measured by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula and the 2012 cystatin C CKD-EPI formula.\n3. A mean seated systolic blood pressure of at least 180 mmHg or a diastolic blood pressure of at least 110 mmHg.\n4. Known secondary hypertension\n5. An acute coronary syndrome, stroke, transient ischemic attack or cardiovascular surgery in the last 3 months.\n6. Hospitalization for heart failure in the past 3 weeks.\n7. Dialysis treatment or expected initiation of dialysis within 3 months of screening.\n8. Women of child bearing potential who are not taking adequate contraception (i.e. \\\u003C1% failure rate).\n9. Planned surgery in the next 12 weeks\n10. Major surgery in the previous 4 weeks.\n11. Use of prednisolone \\>5 mg\u002Fday\n12. Use of any other investigational drug.\n13. Presence of significant comorbidities (e.g., advanced malignancy, advanced liver disease) with a life expectancy of less than 1 year.\n14. A psychiatric, addictive or any disorder that compromises ability to give truly informed consent for participation in this study.\n15. Known hypersensitivity to seaweed, corn, artichoke, grape, melon or to any of the excipients of Endocalyx.\n16. Known hypersensitivity or allergies for milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat and soybeans.\n17. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption.",{"count":52,"type":22},64,[54],"PHASE2","The goal of this randomized, double-blind, placebo-controlled study is to assess whether the food supplement Endocalyx lowers blood pressure in patients with treatment resistant hypertension.",[28],[58,59,60,61],"Glycocalyx","Glycosaminoglycans","non-osmotic sodium storage","hypertension","2025-04-15",{"date":64,"type":34},"2025-04-23",{"date":66,"type":34},"2025-01-21",{"date":68,"type":22},"2028-01-01",{"name":70,"class":41},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Treatment-Resistant Hypertension"]